Jim Simons’s Structure Therapeutics GPCR Stock Holding History

Jim Simons’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.69M	Sell	55,800 -59,400	-52%	-$4.07M	﹤0.01%	1718
2025 Q4	$8.01M	Sell	115,200 -38,700	-25%	-$1.58M	0.01%	1035
2025 Q3	$4.31M	Buy	153,900 +42,000	+38%	+$837K	0.01%	1587
2025 Q2	$2.32M	Buy	111,900 +96,100	+608%	+$2.11M	﹤0.01%	2023
2025 Q1	$273K	Buy	+15,800	New	+$387K	﹤0.01%	2960
2024 Q3	–	Sell	-35,700	Closed	-$1.4M	–	3663
2024 Q2	$1.4M	Buy	+35,700	New	+$1.47M	﹤0.01%	2112
2023 Q3	–	Sell	-32,900	Closed	-$1.37M	–	3830
2023 Q2	$1.37M	Buy	+32,900	New	+$922K	﹤0.01%	2250

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Jim Simons's GPCR Position: Q1 2026 in Review

Jim Simons reduced its Structure Therapeutics (GPCR) stake by 52% in Q1 2026, selling an estimated $4.07M and leaving 55,800 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1718.

Jim Simons first reported a position in GPCR in Q2 2023 and has held it in 7 quarters since. The position peaked at $8.01M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Jim Simons held 55,800 shares of Structure Therapeutics worth $2.69M as of Q1 2026.
Jim Simons sold 59,400 Structure Therapeutics shares in Q1 2026, an estimated $4.07M.
Structure Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1718 holding.
Jim Simons first reported a position in Structure Therapeutics in Q2 2023 and has held it in 7 quarters since.
Jim Simons's Structure Therapeutics position peaked at $8.01M in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.